Caris Life Sciences

Oncology

Interview at ASCO 26 with David Spetzler

ASCO26: AI supercharging gene-based cancer detection, with D...

Pharmaphorum caught up with Caris Life Science's David Spetzler to talk about how agentic AI is empowering whole genome sequencing in cancer detection

News

As year-end nears, pharma groups plump up their pipelines

Bristol Myers Squibb, Sanofi, Pfizer, Roche, and Yarrow Bioscience all added to their pipelines this week in an end-of-year licensing deal flurry.

Oncology

pharmaphorum podcast Episode 198a - Eric Matthews

Advancing the frontiers of cancer diagnostics: Post-ASCO wit...

Post-ASCO 2025, Eric Matthews, chief business officer at Caris Life Sciences, discusses advancing the frontier of cancer diagnostics and treatment.

News

Caris swells its planned IPO, seeking $5.7bn valuation

AI-powered techbio firm Caris Life Sciences has raised the target price for its IPO, pointing to strong demand among investors.

News

Merck taps Caris’ AI expertise in ADC-focused alliance

Germany’s Merck KGaA has partnered with techbio company Caris Discovery in a $1.4 billion alliance that will apply artificial intelligence to the design of antibody-drug c

ASCO26: AI supercharging gene-based cancer detection, with D...

As year-end nears, pharma groups plump up their pipelines

Advancing the frontiers of cancer diagnostics: Post-ASCO wit...

Caris swells its planned IPO, seeking $5.7bn valuation

Merck taps Caris’ AI expertise in ADC-focused alliance

ASCO 2026: Chinese firms take a front seat in oncology, with...

Discover a new era of healthcare panel engagement: Grounded ...

Caris Life Sciences

Editor's Picks